Insider Buying: Orthofix Medical Inc. (NASDAQ:OFIX) Major Shareholder Purchases 1,250 Shares of Stock

Orthofix Medical Inc. (NASDAQ:OFIX - Get Free Report) major shareholder Engine Capital Management, Lp acquired 1,250 shares of the stock in a transaction that occurred on Wednesday, July 2nd. The stock was purchased at an average price of $11.11 per share, for a total transaction of $13,887.50. Following the completion of the acquisition, the insider owned 3,546,057 shares in the company, valued at $39,396,693.27. The trade was a 0.04% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.

Engine Capital Management, Lp also recently made the following trade(s):

• On Wednesday, May 7th, Engine Capital Management, Lp acquired 100,000 shares of Orthofix Medical stock. The stock was purchased at an average price of $12.31 per share, for a total transaction of $1,231,000.00.

Orthofix Medical Trading Up 0.6%

Shares of OFIX stock traded up $0.07 during trading on Thursday, hitting $11.36. 315,711 shares of the stock traded hands, compared to its average volume of 290,128. The firm has a market capitalization of $445.10 million, a P/E ratio of -3.08 and a beta of 0.80. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.71 and a quick ratio of 1.50. The firm's fifty day moving average price is $11.44 and its 200-day moving average price is $14.87. Orthofix Medical Inc. has a 52-week low of $10.24 and a 52-week high of $20.73.

Wall Street Analysts Forecast Growth

OFIX has been the topic of a number of research reports. Barrington Research raised shares of Orthofix Medical to a "strong-buy" rating and set a $16.00 target price on the stock in a research note on Monday, June 23rd. JMP Securities reissued a "market perform" rating on shares of Orthofix Medical in a research note on Friday, June 6th. Finally, Wall Street Zen lowered shares of Orthofix Medical from a "hold" rating to a "sell" rating in a research note on Friday, June 27th. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $21.50.

Institutional Trading of Orthofix Medical

Institutional investors have recently made changes to their positions in the company. Lazard Asset Management LLC purchased a new stake in shares of Orthofix Medical during the 4th quarter valued at approximately $45,000. US Bancorp DE raised its position in Orthofix Medical by 684.6% in the first quarter. US Bancorp DE now owns 5,673 shares of the medical device company's stock valued at $93,000 after purchasing an additional 4,950 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in Orthofix Medical in the fourth quarter valued at approximately $112,000. Tower Research Capital LLC TRC raised its position in Orthofix Medical by 120.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,458 shares of the medical device company's stock valued at $148,000 after purchasing an additional 4,627 shares during the period. Finally, Strs Ohio purchased a new stake in Orthofix Medical in the first quarter valued at approximately $150,000. Hedge funds and other institutional investors own 89.76% of the company's stock.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.